Telix has announced a strategic clinical collaboration with Varian, a Siemens Healthineers company, to develop novel clinical applications that combine Telix’s theranostic products and external beam radiation therapy (EBRT). The initial investigational focus is PSMA-PET imaging

The first patient has been dosed in Part 2 (randomized treatment expansion) of Telix’s Phase 3 ProstACT Global study evaluating our lead prostate cancer therapy candidate, TLX591, in patients with metastatic castration-resistant prostate cancer (mCRPC). The patient was dosed at

Join Telix this week at the 2025 Society of Urologic Oncology (SUO) Annual Meeting, one of the world’s leading international congresses dedicated to advances in urologic cancer care, being held in Phoenix (AZ). Telix will showcase 3 of the Phase 3 studies from its urology

Telix has officially opened Telix Manufacturing Solutions (TMS) in Yokohama, Japan, our first cyclotron facility in the Asia Pacific region. The opening was commemorated with a lecture delivered by Professor Jun Hatazawa, Vice President of the Japan Isotope Association, on

Results from the ZIRCON-X study show that almost half of all patients imaged with Telix’s kidney cancer imaging candidate, TLX250-CDx (Zircaix®), would have undergone a change in clinical management when compared with baseline standard-of-care imaging. New analysis found that

During #WorldQualityWeek, we’re celebrating the culture of Quality that underpins everything we do at Telix. Rujeela, one of our Quality Leads, discusses how Quality is a shared responsibility across every part of the organization - built on collaboration, problem-solving, and a

Final results from the Phase 2 OPALESCENCE trial of TLX250-CDx (⁸⁹Zr-girentuximab) in metastatic triple negative breast cancer (mTNBC) have been published in the European Journal of Nuclear Medicine and Molecular Imaging. The investigator-initiated trial - conducted at

Today, on Veterans Day, we honor the courage, sacrifice, and service of all Veterans. As we pause to recognize their dedication, we are reminded of the importance of supporting their ongoing health and wellbeing. Prostate cancer affects Veterans at higher rates, and awareness,

Join Telix at two upcoming investor conferences to learn more about the company’s growth strategy, commercial progress, and theranostic pipeline. 🔵 Kevin Richardson, CEO, Precision Medicine, will join a fireside chat at the UBS Global Healthcare Conference. 🔵 Richard Valeix,

A new home for Telix clinical trials. Finding the right trial can often be complex. Telix’s new Clinical Trials page is designed to make information about our global theranostic studies easier to find and navigate for patients, carers and the wider community. With clear

These shoes represent the nearly 2,000 Australians diagnosed with a brain tumor each year. Each pair tells a story of a life changed and a call for greater action. Today, Telix proudly supports Brain Tumour Alliance Australia’s Head to the Hill event at Parliament House in

TLX250-CDx (Zircaix®, ⁸⁹Zr-DFO-girentuximab), Telix’s kidney cancer imaging candidate, has been included in latest international guidelines for the molecular imaging of renal masses. Published on the SNMMI website and in The Journal of Nuclear Medicine, the guidelines

The first patient has been dosed in Telix’s SOLACE trial evaluating TLX090 (¹⁵³Sm-DOTMP), a next-generation radiopharmaceutical candidate designed to deliver targeted radiation to bone tumors for durable, non-opioid pain relief. Bone pain affects up to 90% of men with

Up to 1 in 4 men with suspected prostate cancer decline a biopsy, leaving them at risk of misdiagnosis or delayed treatment. As featured on Channel Nine National News, Telix’s BiPASS™ Phase 3 study is exploring a non-invasive alternative to detect the disease. Now recruiting

Telix reports 53% year-over-year revenue growth and raises full-year guidance. Unaudited group revenue for the quarter ended 30 September 2025 was approximately US$206 million. Full-year 2025 revenue guidance has been increased to US$800–820 million. Telix’s therapeutics and

And the winner of the 2025 EANM Sanjiv Sam Gambhir Award is… Dan Cohen from the Weizmann Institute of Science! Congratulations Dan on your achievement, and best of luck for your visitorship at Stanford University. A big thank you to the European Association of Nuclear Medicine

Nuclear medicine is transforming cancer care. During #NuclearMedicineWeek, we’re highlighting how Telix is advancing the field by developing diagnostic imaging and targeted therapies that work together to better see and treat cancer. Our theranostic pipeline is among the most

Telix’s Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400 (177Lu-DOTAGA.Glu.(FAPi)₂), has been published in the Journal of Nuclear Medicine. In a retrospective analysis, Dr. Sanjana Ballal and colleagues from AIIMS, New Delhi, report that TLX400

Join Telix at EANM in Barcelona this Sunday for our sponsored symposium, “From pan-tumor innovation to theranostic precision: Fibroblast activation protein (FAP) and carbonic anhydrase IX (CAIX) case studies.” The event will be chaired by Prof. Antoine Italiano, with

Telix is set for a record-breaking presence at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) – the world’s largest gathering of nuclear medicine professionals. This year, 28 Telix-related abstracts will be presented, highlighting progress across